臨床研究・症例
（First authorのみ）Maruyama A, Ibi A, Sato Y, Tada Y.
Rosai-Dorfman Disease Presenting with Knee Arthralgia. Intern Med. Advance publication.
[https://doi.org/10.2169/internalmedicine.2097-23]
Maruyama A, Kokuzawa A, Yamauchi Y, Kirino Y, et al.
Usefulness of the severity classification for predicting drug-free remission in Japanese patients with adult-onset Still’s disease. Mod Rheumatol 2022; 32: 953-959.
[https://doi.org/10.1093/mr/roab083]
Tada Y, Ono N, Koarada S.
Immediate effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis. Case Rep Rheumatol 2021; 2021: 8876847.
[https://doi.org/10.1080/14397595.2020.1829340]
Maruyama A, Kokuzawa A, Yamauchi Y, Kirino Y, et al.
Clinical features of elderly-onset Adult-onset Still's disease. Mod Rheumatol 2021; 31: 862-868.
[https://doi.org/10.1080/14397595.2020.1829340]
Takeyama Y, Ono N, Shirahama Y, Inoue Y, et al.
Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan. Mod Rheumatol 2021; 31: 408-416.
[https://doi.org/10.1080/14397595.2020.1790778]
Ono N, Inoue Y, Miyamura T, Inoue Y, et al.
The association of airway comorbidities with the clinical phenotypes and outcomes of ANCA-associated vasculitis patients. J Rheumatol 2021; 48: 417-425.
[https://doi.org/10.3899/jrheum.190373]
Tada Y, Sakai M, Nakao Y, Maruyama A, et al.
Placental transfer of tocilizumab in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2019; 58: 1694-1695.
[https://doi.org/10.1093/rheumatology/kez155]
Tada Y, Inokuchi S, Maruyama A, Suematsu R, et al.
Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still’s disease? Rheumatol Int 2019; 39: 97-104.
[https://doi.org/10.1007/s00296-018-4114-1]
Suematsu R, Tashiro S, Ono N, Koarada S, et al.
Successful golimumab therapy in four patients with refractory Takayasu’s arteritis. Mod Rheumatol 2018; 28: 712-715.
[https://doi.org/10.3109/14397595.2015.1134393]
Tokuda Y, Ono N, Sakai M, Sadanaga Y, et al.
A case of granulomatosis with polyangiitis accompanied with strawberry gingivitis, and a review of the literatures. Mod Rheumatol Case Rep 2018; 2: 68-74.
[https://doi.org/10.1080/24725625.2017.1341011]
Koarada S, Tsuboi M, Komine M, Nakao Y, et al.
Effectiveness of Certolizumab Pegol in treating rheumatoid arthritis patients with persistent inflamed residual mono- or oligosynovitis resistant to prior TNF-1 inhibitors. Case Rep Rheumatol 2015; 2015: 348614.
[http://dx.doi.org/10.1155/2015/348614]
Ono N, Niiro H, Ueda A, Sawabe T, et al.
Characteristics of MPO-ANCA-positive granulomatosis with polyangiitis: a retrospective multi-center study in Japan. Rheumatol Int 2015; 35: 555-559.
[http://doi.org/10.1155/2015/348614]
基礎研究
Shirahama Y, Hashimoto A, Ono N, Takeyama Y, et al.
Relationships between type 1 IFN signatures and clinical features of the newly-onset lupus patients in Japan. Mod Rheumatol. [Online ahead of print]
[https://doi.org/10.1093/mr/road015]
Suematsu R, Miyamoto T, Saijo S, Yamasaki H, et al.
Identification of lipophilic ligands of Siglec5 and 14 that modulate innate immune responses. J Biol Chem 2019; 294: 16776-16788.
[https://doi.org/10.1074/jbc.RA119.009835]
Ono N, Kai K, Maruyama K, Sakai M, et al.
The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology (Oxford) 2019; 58: 786-791.
[https://doi.org/10.1093/rheumatology/key386]
Ono N, Murakami K, Chan O, Hall H, et al.
Exposure to sequestered self-antigens in vivo is not sufficient for the induction of autoimmune diabetes.
PLoS One 2017; 12: e0173176.
[https://doi.org/10.1371/journal.pone.0173176]
Tada Y, Ono N, Maruyama A, Tashiro S, et al.
The balance between Foxp3 and Ror-gt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis. BMC Musculoskelet Disord 2016; 17: 290.
[https://doi.org/10.1186/s12891-016-1137-1]
Koarada S, Tashiro S, Tokuda Y, Ono Y, et al.
Persistent expression of CXCR5 on plasmablasts in IgG4-related disease.
Ann Rheum Dis 2015; 74: e32.
[https://dx.doi.org/10.1136/annrheumdis-2014-207207]
Koarada S, Tashiro S, Tokuda Y, Ono Y, et al.
Subsets of RP105-negative plasmablasts in IgG4-related disease. Ann Rheum Dis 2014; 73: e65.
[https://dx.doi.org/10.1136/annrheumdis-2014-206179]
Koarada S, Tada Y.
RP105-negative B cells in systemic lupus erythematosus. Clin Dev Immunol 2012; 2012: 259186.
[https://dx.doi.org/10.1155/2012/259186]
Koarada S, Tada Y, Suematsu R, Soejima S, et al.
Phenotyping of RP105-negative B cell subsets in patients with systemic lupus erythematosus. Clin Dev Immunol 2012; 2012: 198206.
[https://dx.doi.org/10.1155/2012/198206]
Tada Y, Kondo S, Aoki S, Koarada S, et al.
Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice. Arthritis Rheum 2011; 63: 738-748.
[https://doi.org/10.1002/art.30183]
Koarada S, Tada Y, Sohma Y, Haruta Y, et al.
Autoantibody-producing RP105(-) B cells, from patients with systemic lupus erythematosus, showed more preferential expression of BCMA compared with BAFF-R than normal subjects. Rheumatology (Oxford) 2010; 49: 662-670.
[https://doi.org/10.1093/rheumatology/kep437]
書籍
Koarada S ed.
IgG4 Related Disease. Illustrated pathology of novel systemic disease. Nova Science Publishers, New York, USA, 2020.
Koarada S ed.
Frontiers in Arthritis Vol. 3, Rheumatoid Arthritis: A systematic approach. Bentham Science Publishers, Sharjah, UAE, 2018.
Koarada S, Tada Y.
Arthritis and Musculoskeletal Diseases in Systemic Lupus Erythematosus. Rhupus syndrome, Jaccoud’s arthropathy and osteonecrosis. Nova Science Publishers, New York, USA, 2017.
Koarada S, et al.
Corticosteroids and Steroid Therapy: New Research, Nova Science Publishers, New York, USA, 2015.
Koarada S, Tada Y
Fundamental Rheumatological Knowledge of Arthritis Images of the Hand and Case Studies for General Physicians. Nova Science Publishers, New York, USA, 2013.